News
IMA
5.75
-4.33%
-0.26
Weekly Report: what happened at IMA last week (0615-0619)?
Weekly Report · 2d ago
ImageneBio Shareholders Back Directors and Governance Proposals
TipRanks · 6d ago
ImageneBio stockholders approve amended 2025 equity incentive plan at annual meeting
PUBT · 6d ago
Weekly Report: what happened at IMA last week (0608-0612)?
Weekly Report · 06/15 10:25
Weekly Report: what happened at IMA last week (0601-0605)?
Weekly Report · 06/08 10:20
Weekly Report: what happened at IMA last week (0525-0529)?
Weekly Report · 06/01 10:25
ImageneBio CEO presents at Jefferies Global Healthcare Conference
PUBT · 05/27 20:31
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
Barchart · 05/27 15:30
Weekly Report: what happened at IMA last week (0518-0522)?
Weekly Report · 05/25 10:28
Weekly Report: what happened at IMA last week (0511-0515)?
Weekly Report · 05/18 10:28
Analysts Offer Insights on Healthcare Companies: ImageneBio (IMA) and Capricor Therapeutics (CAPR)
TipRanks · 05/11 14:00
ImageneBio Price Target Maintained With a $2.00/Share by Wedbush
Dow Jones · 05/11 12:42
Wedbush Reiterates Underperform on ImageneBio, Maintains $2 Price Target
Benzinga · 05/11 12:31
Weekly Report: what happened at IMA last week (0504-0508)?
Weekly Report · 05/11 10:25
ImageneBio, Inc. reports Q1 results
Seeking Alpha · 05/08 17:16
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/8/26?
TipRanks · 05/08 14:51
ImageneBio price target lowered to $24 from $30 at Leerink
TipRanks · 05/08 10:12
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), ImageneBio (IMA) and Natera (NTRA)
TipRanks · 05/08 10:00
ImageneBio Q1 EPS $(0.95) Misses $(0.70) Estimate
Benzinga · 05/07 20:44
Press Release: ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
Dow Jones · 05/07 20:05
More
Webull provides a variety of real-time IMA stock news. You can receive the latest news about ImageneBio through multiple platforms. This information may help you make smarter investment decisions.
About IMA
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.